FCN-437c is under clinical development by Fochon Pharmaceutical and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FCN-437c’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FCN-437c overview

FCN-437c is under development for the treatment of solid tumors including ER-positive and HER2-negative metastatic breast cancer, breast cancer and non-small cell lung cancer. The drug candidate is formulated as a capsule, tablet and administered through the oral route. It acts by targeting cyclin-dependent kinase (CDK) 4 and 6.

Fochon Pharmaceutical overview

Chongqing Fochon Pharmaceutical Co., Ltd. is engaged in the research and development of chemical drugs.

For a complete picture of FCN-437c’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.